Stay updated with the latest catalent news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on catalent topics.
Aug 1 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's (SASY.PA), opens new tab Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called c ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.